Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
- PMID: 10812530
- DOI: 10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
Abstract
Pramipexole, a dopamine D2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features. Three daily dose levels (0.375 mg, 1.0 mg, and 5.0 mg) were compared to fluoxetine (Prozac) at 20 mg and placebo in a randomized, double-blind, parallel-group study. After a 1 week placebo run-in period, patients were treated for 8 weeks, had a post-study follow-up (week 9), and were evaluated primarily with the Hamilton Psychiatric Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Clinician's Global Impressions-Severity of Illness scale (CGI-SI). All patients who received one dose of study medication were included in the observed-case analysis (no missing data were replaced). Results indicated that by endpoint (week 8), patients receiving pramipexole at the 1.0 mg per day dose had significant improvement over baseline compared to the placebo group by measure of the HAM-D, MADRS, and CGI-SI. Significant improvement in this dose group was seen at other timepoints as well. The most obvious improvement was seen in the pramipexole 5.0 mg group, although a substantial dropout rate for this group precluded statistical tests vs. placebo late in the study. Patients taking fluoxetine also showed significant improvements at endpoint on the MADRS and earlier in the study on the HAM-D. No new or unusual safety concerns were generated during this study. Pramipexole helped safely alleviate the symptoms of depression at 1.0 mg per day and especially in those patients who could tolerate the escalation to 5 mg per day.
Similar articles
-
Pramipexole in treatment-resistant depression: a 16-week naturalistic study.Bipolar Disord. 2002 Oct;4(5):307-14. doi: 10.1034/j.1399-5618.2002.01171.x. Bipolar Disord. 2002. PMID: 12479663 Clinical Trial.
-
Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.Am J Psychiatry. 2004 Mar;161(3):564-6. doi: 10.1176/appi.ajp.161.3.564. Am J Psychiatry. 2004. PMID: 14992985 Clinical Trial.
-
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.Am J Geriatr Psychiatry. 2006 Apr;14(4):361-70. doi: 10.1097/01.JGP.0000194645.70869.3b. Am J Geriatr Psychiatry. 2006. PMID: 16582045 Clinical Trial.
-
Venlafaxine extended-release: a review of its use in the management of major depression.CNS Drugs. 2001;15(8):643-69. doi: 10.2165/00023210-200115080-00007. CNS Drugs. 2001. PMID: 11524036 Review.
-
Treatment of depressive symptoms in Parkinson's disease.Eur J Neurol. 2011 Mar;18 Suppl 1:11-5. doi: 10.1111/j.1468-1331.2010.03325.x. Eur J Neurol. 2011. PMID: 21255198 Review.
Cited by
-
Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.CNS Neurosci Ther. 2010 Jun;16(3):e1-17. doi: 10.1111/j.1755-5949.2010.00146.x. Epub 2010 Apr 8. CNS Neurosci Ther. 2010. PMID: 20406250 Free PMC article. Review.
-
Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats.Psychopharmacology (Berl). 2011 Jan;213(1):11-8. doi: 10.1007/s00213-010-2006-5. Epub 2010 Sep 4. Psychopharmacology (Berl). 2011. PMID: 20814781 Free PMC article.
-
Switching and combining of dopamine agonists.J Neurol. 2004 Sep;251 Suppl 6:VI/19-23. doi: 10.1007/s00415-004-1605-7. J Neurol. 2004. PMID: 15675720 Review.
-
Current status of symptomatic medical therapy in Parkinson's disease.Neurotherapeutics. 2008 Apr;5(2):164-80. doi: 10.1016/j.nurt.2007.12.001. Neurotherapeutics. 2008. PMID: 18394561 Free PMC article. Review.
-
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.CNS Drugs. 2011 Feb;25(2):109-27. doi: 10.2165/11538980-000000000-00000. CNS Drugs. 2011. PMID: 21254788 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical